The interrelationship between FGF23 and inflammation opens new research pathways regarding the development and progression of atherosclerosis in subjects with CKD, with translational clinical applicability from diagnostic, prognostic, and therapeutic perspectives focused on modulating FGF23. This evidence concerns the gene FGF23 and atherosclerosis.